CLINICAL_TRIALS
trial_result
· 2023-02-17
Clinical Trial Update: Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) [Phase 3]
Summary
Phase 3 trial MK-3475-913 evaluated pembrolizumab as first-line therapy for advanced Merkel cell carcinoma; the study has completed and results were posted in F…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Merkel Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2023-02-17